Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer

J Franek, JC Cappelleri, KA Larkin-Kaiser… - Future …, 2019 - Taylor & Francis
Here, we compare the relative clinical efficacy of EGFR-targeted tyrosine kinase inhibitors
(EGFR TKIs) for EGFR-positive advanced non-small-cell lung cancer (NSCLC). The authors …
被引用次数：24 相关文章

Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer

J Franek, JC Cappelleri… - Future oncology …, 2019 - pubmed.ncbi.nlm.nih.gov
Here, we compare the relative clinical efficacy of EGFR-targeted tyrosine kinase inhibitors
(EGFR TKIs) for EGFR-positive advanced non-small-cell lung cancer (NSCLC). The authors …

Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer.

J Franek, JC Cappelleri, KA Larkin-Kaiser… - Future Oncology …, 2019 - europepmc.org
Here, we compare the relative clinical efficacy of EGFR-targeted tyrosine kinase inhibitors
(EGFR TKIs) for EGFR-positive advanced non-small-cell lung cancer (NSCLC). The authors …

Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer

J Franek, JC Cappelleri, KA Larkin-Kaiser… - Future …, 2019 - search.proquest.com
Here, we compare the relative clinical efficacy of EGFR-targeted tyrosine kinase inhibitors
(EGFR TKIs) for EGFR-positive advanced non-small-cell lung cancer (NSCLC). The authors …